Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?
Follicular lymphomas (FL) account for 30% of non-Hodgkin's lymphomas (NHL). Their evolution is heterogeneous. Some patients present with indolent forms undergoing several relapses while in other patients the disease evolves abruptly toward aggressive NHL. This is why accurate prognostic indices are required so that treatment strategies may be optimized for each patient and so that trials may be conducted in groups of patients that are as homogeneous as possible. The Follicular Lymphoma International Prognostic Index (FLIPI) has been designed to separate patients into 3 groups with significantly different hazard ratios for death. Its accuracy has been confirmed in several studies. The FLIPI2 was designed more recently to separate patients with significantly different hazard ratios for progression/relapse in the era of anti-CD20 monoclonal antibody treatments. Gene profile studies have shown that the prognosis of FL is mainly related to the type, number, and activation of immune cells in the microenvironment of lymphomatous follicles. Immunohistochemical studies suggest that macrophages, CD4+ T cells and among them T-regulatory cells (T-regs) and programed death-1 cells (PD-1 cells) play a major role in the outcome of FLs. However, additional confirmatory studies are required due to discrepancies in results. Up to now, these biological study results are more useful for approaching the pathophysiology of FL rather than to be used as prognostic tools in clinical practice.
Solal-Céligny
Ph
P
Centre J. Bernard, Service d'Hématologie, Le Mans, France. p.solal-celigny@centre-jean-bernard.org
Cahu
X
X
Cartron
G
G
D006801:Humans; D008224:Lymphoma, Follicular / Q000175:diagnosis* / Q000276:immunology; D011379:Prognosis; D012307:Risk Factors; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
J Clin Oncol. 2008 Jan 20;26(3):440-6
18086798
J Clin Oncol. 2009 Mar 20;27(9):1470-6
19224853
J Clin Oncol. 2004 Dec 1;22(23):4711-6
15483015
Annu Rev Immunol. 2008;26:677-704
18173375
Clin Cancer Res. 2010 Jan 15;16(2):637-50
20068089
J Clin Oncol. 2009 Sep 20;27(27):4555-62
19652063
Br J Haematol. 2009 May;145(4):468-80
19344401
Blood. 2005 May 1;105(9):3428-33
15637137
Leuk Res. 2006 Mar;30(3):277-82
16112730
J Clin Oncol. 2006 Nov 1;24(31):5052-9
17033038
J Clin Oncol. 2006 Apr 1;24(10):1582-9
16575009
Int J Cancer. 2009 Jan 1;124(1):239-44
18814264
J Clin Invest. 2004 Nov;114(9):1209-17
15520849
Blood. 2005 Dec 1;106(12):3725-32
16123223
J Clin Oncol. 1997 Mar;15(3):1110-7
9060552
Clin Cancer Res. 2007 Oct 1;13(19):5784-9
17908969
N Engl J Med. 2004 Nov 18;351(21):2159-69
15548776
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):388-97
17255259
J Clin Oncol. 1999 Aug;17(8):2499-505
10561315
Blood. 2004 Sep 1;104(5):1258-65
15126323
Apoptosis. 2003 Jan;8(1):45-53
12510151
Blood. 2010 Jan 14;115(2):289-95
19901260
J Clin Oncol. 2005 Aug 1;23(22):5019-26
15983392
J Clin Invest. 2004 Dec;114(11):1640-9
15578096
J Clin Oncol. 2007 Feb 1;25(4):390-8
17200149
Cancer. 1982 May 15;49(10):2112-35
6896167
Genes Chromosomes Cancer. 2004 Mar;39(3):195-204
14732921
Blood. 2009 Jan 29;113(5):1053-61
18978208
Ann Oncol. 2005 Sep;16(9):1508-13
15939718
Curr Opin Immunol. 2007 Jun;19(3):309-14
17433872
Leuk Lymphoma. 2007 Mar;48(3):452-3
17454582
Blood. 1990 Mar 1;75(5):1154-62
2306520
Blood. 1994 Aug 15;84(4):1043-9
8049424
J Clin Oncol. 2007 Feb 10;25(5):579-86
17242396
J Clin Oncol. 2008 Oct 1;26(28):4579-86
18662969
Best Pract Res Clin Haematol. 2005 Mar;18(1):27-56
15694183
Blood. 2006 Nov 1;108(9):2957-64
16825494
Br J Haematol. 2010 May;149(3):455-7
20064149
Blood. 2006 Sep 1;108(5):1504-8
16690968
J Clin Oncol. 2007 May 20;25(15):1986-92
17420513
J Clin Oncol. 1994 Jul;12(7):1343-8
8021724
Blood. 2002 Jun 15;99(12):4265-75
12036852
Clin Lymphoma Myeloma. 2008 Oct;8(5):287-93
18854283
J Immunol. 2002 Sep 1;169(5):2756-61
12193750
J Clin Oncol. 2010 Feb 10;28(5):822-9
20026809
J Clin Oncol. 1994 Jul;12(7):1340-2
8021723
Blood. 2008 May 1;111(9):4764-70
18174380
Blood. 2005 Sep 15;106(6):2169-74
15933054
Cancer Res. 2009 Jul 1;69(13):5522-30
19509224
N Engl J Med. 1993 Sep 30;329(14):987-94
8141877
Ann Oncol. 2010 Jun;21(6):1196-1202
19875761
J Clin Oncol. 2010 May 1;28(13):2246-52
20368567
Acta Haematol. 2009;122(4):193-9
19887775